Rally in Chinese healthcare signals a structural shift, not a fleeting rebound

CHINESE healthcare is leading Asia’s capital markets in 2025, transforming from a domestic growth story into a global force in innovation and investment. This rally has been anchored by blockbuster initial public offerings (IPOs) in Hong Kong, including Hengrui Pharma’s US$1.5 billion listing and DualityBio’s oversubscribed debut, which together highlight the depth of institutional demand and the sector’s growing role as a cornerstone of regional equity markets.

Both the Hang Seng Biotech and Healthcare Index have soared this year, rising 83 per cent and 74 per cent year-to-date, respectively – dwarfing the broader Hang Seng Index’s 27 per cent gain.

More than a cyclical rebound, this momentum signals the start of a structural shift. The healthcare sector is emerging as the frontrunner in driving innovation, attracting investment, and shaping market leadership, not just in Asia but globally.